Publications by authors named "R Greinwald"
Article Synopsis
- Transglutaminase 2 (TG2) is crucial in the development of celiac disease by modifying gluten peptides, leading to a heightened immune response against gluten.
- The study evaluates the effectiveness of the TG2 inhibitor ZED1227 in preventing gluten-induced damage in celiac patients on a gluten-free diet, revealing that it significantly safeguards intestinal health at the molecular level.
- Findings indicate that ZED1227 treatment helps maintain healthy gene expression related to the gut's structure and function, and suggest a potential benefit in personalized treatment strategies based on specific genetic markers in celiac patients.
Background & Aims: The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of remission in patients with mild to moderate ulcerative colitis (UC) and inadequate response to mesalamine.
Methods: LT-02 was evaluated in a multicenter double-blind, randomized, placebo-controlled study comprising a 12-week induction trial (PCG-2), followed by a 48-week maintenance trial (PCG-4). In PCG-2, patients were randomized 1:1:1 to treatment with 0.
Mesalazine granules promote disease clearance in patients with mild-to-moderate ulcerative colitis.
United European Gastroenterol J
October 2023
Background: Over the past decade, treatment targets for ulcerative colitis (UC) have become more stringent, incorporating multiple parameters. Recently, the concept of 'disease clearance'-defined as combined clinical, endoscopic, and histological remission-has been proposed as an ultimate endpoint in treating UC.
Objective: To determine the rates of disease clearance in patients with mild-to-moderate UC treated with different doses of mesalazine granules as induction therapy.
Article Synopsis
- The enzyme transglutaminase 2 (TG2) is crucial in the development of celiac disease, primarily found outside cells in the small intestine and sometimes within the intestinal lining.
- ZED1227, a potential treatment for celiac disease, is an inhibitor designed to prevent TG2 from modifying gliadin peptides, which trigger the disease.
- Research showed that after administering ZED1227, it accumulates in the villous enterocytes of the intestine, effectively inhibiting TG2 activity before gliadin peptides can enter deeper tissue layers.
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
J Crohns Colitis
November 2022
Background And Aims: Proctitis is the least extensive type of ulcerative colitis, for which rectal therapy is rarely studied and is underused. This study evaluated the efficacy, safety, and patient's preference of a novel formulation of budesonide suppository 4 mg, compared with a commercially available budesonide rectal foam 2 mg, for the treatment of mild to moderate ulcerative proctitis.
Methods: This was a randomised, double-blind, double-dummy, active-controlled trial.